<br>        Inclusion Criteria:<br><br>          -  The subject and the authorized legal representative must understand the nature of the<br>             study and be able to comply with protocol requirements. The representative must sign<br>             an Informed Consent Document and the subject must provide Written Assent.<br><br>          -  The subject (male or female) must be between 7-17 (inclusive) years of age at<br>             screening.<br><br>          -  The subject must have a primary diagnosis of Conduct Disorder [CD] (312.8),<br>             Oppositional Defiant Disorder [ODD] (313.81) or Disruptive Behavior Disorder not<br>             otherwise specified [DBD-NOS] (312.9) as defined by DSM-IV criteria and confirmed by<br>             the Kiddie-SADS-PL.<br><br>          -  At the screening visit (Visit 1), subjects must have a score of 21 or more on the sum<br>             of the scales for conduct problems and for oppositional behaviour in the NCBRF-TIQ.<br><br>          -  In the investigator's opinion, the subject must be likely to benefit from the<br>             therapy.<br><br>          -  The subject is willing and able to discontinue any medications that are prohibited in<br>             this study (see Concomitant Medications table, Section 3.5.1). Any such medications<br>             must be discontinued at least 5 half-lives  prior to the administration of<br>             double-blinded study medication.<br><br>          -  Patients who are receiving prohibited medications are to be considered for the<br>             protocol only If discontinuation of the medication does not compromise the welfare of<br>             the patient and/or alternative medication that is allowed by the protocol is<br>             available and appropriate for the patient. Psychotropic medications should be tapered<br>             down per accepted medical practice and the specific package insert instead of being<br>             abruptly discontinued.<br><br>          -  Females of childbearing potential may be included provided that they are not<br>             pregnant, not nursing, and are practicing effective contraception and meet all of the<br>             following criteria:<br><br>               -  Are instructed and agree to avoid pregnancy during the study.<br><br>               -  Have a negative pregnancy test (ß-HCG) at screening and Visit 2.<br><br>               -  Use one of the following birth control methods:<br><br>                    -  an oral contraceptive agent, an intrauterine device (ILTD), an implantable<br>                       contraceptive (e.g. Norplant), transdermal hormonal contraceptive (e.g.<br>                       Ortho-Evra), or an injectable contraceptive (e.g. Depo-Provera) for at<br>                       least one month prior to entering the study and will continue its use<br>                       throughout the study; or<br><br>                    -  a barrier method of contraception, e.g., condom and / or diaphragm with<br>                       spermicide while participating in the study.<br><br>                    -  abstinence for at least 3 months before the start of the study and<br>                       intention to abstain from sexual activity during the study period.<br><br>          -  Subjects must have an IQ > 55 best tested with the HAWIK-III, alternatively with the<br>             CFT-20 or K-ABC.<br>